Urologie pro praxi 2/2022
Non-metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer is the incurable form of prostate cancer, carrying the poorest prognosis, and can develop from non-metastatic castration-resistant prostate cancer. There have been three trials assessing treatments in the specific setting of nmCRPC; PROSPER (enzalutamide), SPARTAN (apalutamide), ARAMIS (darolutamide). The results include the delay of metastatic disease development, prevention of symptoms, and a benefit in overall survival.
Keywords: non‑metastatic castration‑resistant prostate cancer, enzalutamide, apalutamide, darolutamide.
